Phase Ib Study: Venetoclax/Azacitidine in Treatment-Naive Higher-Risk MDS

Source: 2021 American Society of Hematology Annual Meeting*
Download Slideset
December 11-14, 2021; Atlanta, Georgia
In this phase Ib study in previously untreated higher-risk MDS, venetoclax plus azacitidine was safe and appeared to induce rapid, durable responses and a high remission rate, with molecular responses observed across key mutational profiles.
Format: Microsoft PowerPoint (.ppt)
File Size: 571 KB
Released: December 15, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Daiichi Sankyo, Inc.
GlaxoSmithKline
Incyte Corporation
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings